Table 1 Trial characteristics
Studies | Year | Reference type | Cases (risedronate /C) | Mean age (risedronate /C) | Female% | Risedronate group | Control group | Follow-up |
|---|---|---|---|---|---|---|---|---|
Kinov | 2005 | RCT | 12/12 | 58.3/56 | 62.5% | 35 mg risedronate | No treatment | A minimum of half year |
Yamasaki | 2006 | RCT | 19/21 | 66.8/66.7 | 90% | 2.5 mg/day orally | Placebo | A minimum of half year |
Skoldenberg | 2011 | RCT | 36/37 | 61.2/60.3 | 59% | 35 mg risedronate | Placebo | A minimum of 1 year |
Muren | 2015 | RCT | 30/31 | 62.5/60.8 | 38% | 35 mg risedronate | Placebo | A minimum of 4 years |